Improvement bioavailability of silymarin ameliorates severe dyslipidemia associated with metabolic syndrome

References

• Alvergnas M, Richert L, Blanchard N, et al. (2009). Regulation of CYP4A expression by bezafibrate in primary culture of rat and human hepatocytes: interspecies difference and influence of N-acetylcysteine. Toxicol In Vitro 23:1259–67
   PubMed Web of Science ®Google Scholar
• Barter PJ, Puranik R, Rye KA. (2007). New insights into the role of HDL as an anti-inflammatory agent in the prevention of cardiovascular disease. Curr Cardiol Rep 9:493–8
   PubMedGoogle Scholar
• Berge KE, Tian H, Graf GA, et al. (2000). Accumulation of dietary cholesterol in sitosterolemia caused by mutation in adjacent ABC transporters. Science 290:1771–5
   PubMed Web of Science ®Google Scholar
• Brown JM, Yu L. (2009). Oppositing gatekeepers of apical sterol transport: niemann-Pick C1-Like1 (NPC1L1) and ATP-binding cassette transporters G5 and G8 (ABCG5/ABCG8). Immunol Endocr Metab Agents Med Chem 9:18–29
   PubMedGoogle Scholar
• Calani L, Brighenti F, Bruni R, Del Rio D. (2012). Absorption and metabolism of milk thistle flavonolignans in humans. Phytomedicine 20:40–6
   PubMed Web of Science ®Google Scholar
• Chiang JY, Kimmel R, Stroup D. (2001). Regulation of cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription by the liver orphan receptor (LXRalpha). Gene 262:257–65
   PubMed Web of Science ®Google Scholar
• Cullen P. (2000). Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cadiol 89:943–9
   Google Scholar
• Davidson MH. (2011). Focusing on high-density lipoprotein for coronary heart disease risk reduction. Cardiol Clin 29:105–22
   PubMed Web of Science ®Google Scholar
• Di Pierro F, Callegari A, Carotenuto D, Tapia MM. (2008). Clinical efficacy, safety and tolerability of BIO-C (micronized Silymarin) as galactagogue. Acta Biomed 79:205–10
   PubMedGoogle Scholar
• Enjalbert F, Rapior S, Nouguier-Soulé J, et al. (2002). Treatment of amatoxin poisoning: 20-year retrospective analysis. J Toxicol Clin Toxicol 40:715–57
   PubMed Web of Science ®Google Scholar
• Ferenci P, Beinhardt S. (2013). Silibinin: an old drug in the high tech era of liver transplantation. J Hepatol 58:409–11
   PubMed Web of Science ®Google Scholar
• Galassi A, Reynolds K, He J. (2006). Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med 119:812–19
   PubMed Web of Science ®Google Scholar
• Gordon T, Castelli WP, Hjortland MC, et al. (1977). High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 62:707–14
   PubMed Web of Science ®Google Scholar
• Habtemariam S, Varghese GK. (2014). The antidiabetic therapeutic potential of dietary polyphenols. Curr Pharm Biotechnol 15:391–400
   PubMed Web of Science ®Google Scholar
• Ji W, Guo L, Lian J, Gong B. (2008). Hypolipidaemic mechanisms of action of CM108 (a flavone derivative) in hyperlipidaemic rats. J Pharm Pharmacol 60:1207–12
   PubMed Web of Science ®Google Scholar
• Kidd P, Head K. (2005). A review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybin-phosphatidylcholine complex (Siliphos). Altern Med Rev 10:193–203
   PubMed Web of Science ®Google Scholar
• Klimes I, Vrána A, Kunes J, et al. (1995). Hereditary hypertriglyceridemic rat: a new animal model of metabolic alterations in hypertension. Blood Press 4:137–42
   PubMedGoogle Scholar
• Lake BG. (1990). Preparation and characterization of microsomal fraction for studies on xenobiotic metabolism. In: Snell EK, Mullock B, eds. Biochemical toxicology and practical approach. Oxford-Washington, DC: IRL Press, 183--215
   Google Scholar
• Morazzoni P, Montalbetti A, Malandrino S. (1992). Comparative biliary excretion of silybin after single oral doses of silipide and silymarin in rats. First International Symposium on Natural Drugs and the Digestive Tract, Naples, Italy. Seattle (WA): Indena USA Inc. Available from: www.indenausa.com
   Google Scholar
• Morazzoni P, Montalbetti A, Malandrino S, Pifferi G. (1993). Comparative pharmacokinetics of silipide and silymarin in rats. Eur J Drug Metab Pharmacokinet 18:289–97
   PubMed Web of Science ®Google Scholar
• Mottillo S, Filion KB, Genest J, et al. (2010). The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 56:1113–32
   PubMed Web of Science ®Google Scholar
• Navab M, Reddy ST, Van Lenten BJ, Fogelman AM. (2011). HDL and cardiovascular disease: atherogenic and antheroprotective mechanisms. Nat Rev Cardiol 8:222–32
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. (2007). Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 298:299–308
   PubMed Web of Science ®Google Scholar
• Orolin J, Vecera R, Jung D, et al. (2007). Hypolipidemic effects of silymarin are not mediated by the peroxisome proliferator-activated receptor alpha. Xenobiotica 37:725–35
   PubMed Web of Science ®Google Scholar
• Patel J, Patel R, Khambholja K, Patel N. (2009). An overview of phytosomes as an advanced herbal drug delivery system. J Pharm Sci 4:363–71
   Google Scholar
• Prasad H, Ryan DA, Ceizo MF, Stapleton D. (2012). Metabolic syndrome: definitive and therapeutic implications. Postgrad Med 124:21–30
   PubMed Web of Science ®Google Scholar
• Qi N, Kazdova L, Zidek V, et al. (2002). Pharmacogenetic evidence that cd36 is a key determinant of the metabolic effects of pioglitazone. J Biol Chem 277:48501–7
   PubMed Web of Science ®Google Scholar
• Repa JJ, Berge KE, Pomajzl C, et al. (2002). Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. J Biol Chem 277:18793–800
   PubMed Web of Science ®Google Scholar
• Roman LJ, Palmer CN, Clark JE, et al. (1993). Expression of rabbit cytochromes P4504A which catalyze the omega-hydroxylation of arachidonic acid, fatty acids and prostaglandins. Arch Biochem Biophys 307:57–65
   PubMed Web of Science ®Google Scholar
• Sarwar N, Danesh J, Eiriksdottir G, et al. (2007). Triglycerides and the risk of coronary heart disease. Circulation 115:450–8
   PubMed Web of Science ®Google Scholar
• Sharma R, Lake BC, Gibson GG. (1988). Co-induction of microsomal cytochrome P-452 and the peroxisomal fatty acid beta-oxidation pathway in the rat by clofibrate and di-(2-ethylhexyl)phthalate. Dose-response studies. Biochem Pharmacol 37:1203–6
   PubMed Web of Science ®Google Scholar
• Skottová N, Krecman V. (1998). Silymarin as a potential hypocholesterolaemic drug. Physiol Res 47:1–7
   PubMed Web of Science ®Google Scholar
• Skottová N, Vecera R, Urbánek K, et al. (2003). Effects of polyphenolic fraction of silymarin on lipoprotein profile in rats fed cholesterol-rich diets. Pharm Res 47:17–26
   Google Scholar
• Sobolová L, Skottová N, Vecera R, Urbánek K. (2006). Effect of silymarin and its polyphenolic fraction on cholesterol absorption in rats. Pharmacol Res 53:104–12
   PubMed Web of Science ®Google Scholar
• Spady DK, Cuthbert JA, Willard MN, Meidall RS. (1996). Feedback regulation of hepatic 7alpha-hydroxylase expression by bile salts in the hamster. J Biol Chem 271:18623–31
   PubMed Web of Science ®Google Scholar
• Stolba P, Dobesová Z, Husek P, et al. (1992). The hypertriglyceridemic rat as a genetic model of hypertension and diabetes. Life Sci 51:733–40
   PubMed Web of Science ®Google Scholar
• Vecera R, Zacharova A, Orolin J, et al. (2011). The effect of silymarin on expression of selected ABC transporters in the rat. Vet Med 56:59–62
   Web of Science ®Google Scholar
• Valenzuela A, Garrido A. (1994). Biochemical bases of the pharmacological action of the flavonoid silymarin and of its structural isomer silibinin. Biol Res 27:105–12
   PubMed Web of Science ®Google Scholar
• Vrána A, Kazdová L. (1990). The hereditary hypertriglyceridemic nonobese rat: an experimental model of human hypertriglyceridemia. Transplant Proc 22:2579
   PubMed Web of Science ®Google Scholar
• Xu G, Pan LX, Li H, et al. (2004). Dietary cholesterol stimulates CYP7A1 in rats because farnesoid X receptor is not activated. Am J Physiol Gastrointest Liver Physiol 286:G730–5
   PubMed Web of Science ®Google Scholar
• Yu L, York J, von Bergmann K, et al. (2003). Stimulation of cholesterol excretion by the liver X receptor agonist requires ATP-binding cassette transporters G5 and G8. J Biol Chem 278:15565–70
   PubMed Web of Science ®Google Scholar
• Zhang S, Zheng L, Dong D, et al. (2013). Effects of flavonoids from Rosa laevigata Michx fruit against high-fat diet-induced non-alcoholic fatty liver disease in rats. Food Chem 141:2108–16
   PubMed Web of Science ®Google Scholar
• Zicha J, Pechanová O, Cacányiová S, et al. (2006). Hereditary hypertriglyceridemic rat: a suitable model of cardiovascular disease and metabolic syndrome? Physiol Res 55:S49–63
   PubMed Web of Science ®Google Scholar